Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenue | 92,100 | 71,539 | 175,227 | 131,658 |
| Costs and expenses: | ||||
| Cost of goods sold | 12,512 | 11,898 | 23,086 | 20,626 |
| Research and development | 10,669 | 8,055 | 19,452 | 15,808 |
| Selling, general and administrative | 61,035 | 44,393 | 114,179 | 88,411 |
| Amortization of intangible assets | 2,711 | 2,711 | 5,421 | 5,421 |
| Total costs and expenses | 86,927 | 67,057 | 162,138 | 130,266 |
| Income from operations | 5,173 | 4,482 | 13,089 | 1,392 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s R&D?
- Xeris Biopharma Holdings, Inc. (XERS) reported R&D of $10.67M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s R&D changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s R&D increased by 32.5% year-over-year, from $8.06M to $10.67M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s R&D?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s R&D has grown at a 5.5% compound annual growth rate (CAGR), from $25.16M to $31.17M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Xeris Biopharma Holdings, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude